Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371166 | 0.90 | PTGS2 (0.66) | PTGS2PTGS1MAPK14CSNK1A1CSNK1D | |
| SCHEMBL6595243 | 0.87 | MAPK14 (0.53) | PTGS2PTGS1MAPK14PDPK1CA1 | |
| SCHEMBL5377112 | 0.87 | PTGS1 (0.54) | PTGS2PTGS1MAPK14CSNK1A1CSNK1D | |
| SCHEMBL5366953 | 0.85 | MAPK14 (0.54) | PTGS2PTGS1MAPK14CYP2C9PDPK1 | |
| SCHEMBL5375485 | 0.83 | PTGS2 (0.55) | PTGS2PTGS1MAPK14CSNK1A1CSNK1D | |
| SCHEMBL5373901 | 0.77 | PTGS2 (0.59) | PTGS2PTGS1MAPK14 | |
| SCHEMBL5368778 | 0.77 | PTGS2 (0.67) | PTGS2PTGS1MAPK14CSNK1A1CSNK1D | |
| SCHEMBL5369160 | 0.76 | PTGS1 (0.68) | PTGS2PTGS1MAPK14CSNK1A1CSNK1D | |
| SCHEMBL5365336 | 0.76 | MAPK14 (0.56) | PTGS2PTGS1MAPK14CSNK1A1CSNK1D | |
| SCHEMBL6594280 | 0.74 | PTGS1 (0.57) | PTGS2PTGS1MAPK14CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223772-B1 | Pyrazolopyridine derivatives as selective cox-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-29 | — | — | US | claimed |
| CN-1263755-C | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAXO GROUP LTD (GB) | 2006-07-12 | — | — | CN | claimed |
| EP-1127058-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2004-09-01 | — | — | EP | claimed |
| CN-1332741-A | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAZO GROUP LTD (GB) | 2002-01-23 | — | — | CN | claimed |
| EP-1127058-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-08-29 | — | — | EP | claimed |
| WO-2000026216-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-05-11 | — | — | WO | claimed |
| US-7223772-B1 | Pyrazolopyridine derivatives as selective cox-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| CN-1263755-C | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAXO GROUP LTD (GB) | 2006-07-12 | — | — | CN | disclosed |
| EP-1127058-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2004-09-01 | — | — | EP | disclosed |
| CN-1332741-A | Pyrazolopyridine derivatives as selective COX-2 inhibitors | GLAZO GROUP LTD (GB) | 2002-01-23 | — | — | CN | disclosed |
| EP-1127058-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000026216-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |